CIK 0000882796
- Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 621413174
- Phone
- +1 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-12-20 | Stonehouse Jon P President & CEO | Grant or award · Emp. Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2017-12-01 | INGRAM ROBERT ALEXANDER Director | Grant or award | +3,690 | $5.08 | $19K | 15,130 |
| 2017-12-01 | Hutson Nancy J Director | Grant or award | +1,968 | $5.08 | $10K | 36,135 |
| 2017-11-13 | Sheridan William P Senior VP - CMO | Sale | −64,310 | $4.72 | $304K | 23,855 |
| 2017-09-18 | Cohen Fred E Director | Exercise or conversion | +54,250 | $4.27 | $232K | 173,660 |
| 2017-09-18 | Cohen Fred E Director | Sale | −54,250 | $5.42 | $294K | 119,410 |
| 2017-09-18 | Cohen Fred E Director | Exercise or conversion · Non-Qualified Stock Option | −54,250 | 0 | ||
| 2017-09-01 | INGRAM ROBERT ALEXANDER Director | Grant or award | +3,676 | $5.10 | $19K | 11,440 |
| 2017-09-01 | Hutson Nancy J Director | Grant or award | +1,960 | $5.10 | $10K | 34,167 |
| 2017-08-31 | Powell Lynne Senior VP - CCO | Grant or award · Emp. Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2017-08-31 | Barnes Alane P VP, General Counsel & Corp Sec | Grant or award · Emp. Stock Option (Right to Buy) | +18,600 | 18,600 | ||
| 2017-08-31 | Sheridan William P Senior VP - CMO | Grant or award · Emp. Stock Option (Right to Buy) | +33,900 | 33,900 | ||
| 2017-08-31 | Babu Yarlagadda S Senior VP - Drug Discovery | Grant or award · Emp. Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2017-08-31 | STAAB THOMAS R II Senior Vice President and CFO | Grant or award · Emp. Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2017-08-31 | Stonehouse Jon P President & CEO | Grant or award · Emp. Stock Option (Right to Buy) | +40,710 | 40,710 | ||
| 2017-06-01 | INGRAM ROBERT ALEXANDER Director | Grant or award | +1,941 | $5.15 | $10K | 7,764 |
| 2017-06-01 | Hutson Nancy J Director | Grant or award | +1,941 | $5.15 | $10K | 32,207 |
| 2017-06-01 | Cohen Fred E Director | Grant or award | +1,941 | $5.15 | $10K | 119,410 |
| 2017-05-24 | Patel Sanj K Director | Grant or award · Automatic Stock Option Grant | +30,000 | 30,000 | ||
| 2017-05-24 | LEE KENNETH B JR Director | Grant or award · Automatic Stock Option Grant | +30,000 | 30,000 |
Page 39 of 45 · 882 trades